Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
2 drugs in development
By Therapeutic Area
top 1
R&D Momentum
47/100
Pipeline Velocity
15/100
Trial Completion Rate
96/100
Pipeline Concentration
56/100
Pipeline Freshness
0/100
Strategic Signals
Activity
Last 14 days
Changes in Intestinal Permeability and Systemic Inflammation Following Fast Food Overfeeding.
Effects of Antagonizing the Ghrelin Receptor in Individuals With Obesity on Treatment With Semaglutide
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)